deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01290939

Bevacizumab and Lomustine for Recurrent GBM

Phase III Trial Exploring the Combination of Bevacizumab and Lomustine in Patients With First Recurrence of a Glioblastoma

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Cognition Disorders Disability Evaluation Glioblastoma Multiforme
Interventions DNA methylation analysis bevacizumab cognitive assessment laboratory biomarker analysis lomustine quality-of-life assessment
Updated 8 times since 2017 Last updated: Feb 11, 2021 Started: Oct 31, 2011 Primary completion: Oct 31, 2015 Completion: Apr 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cognition Disorders and Disability Evaluation and is currently completed. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Mar 2020 · 21 months · monthly snapshotActive Not Recruiting~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshotUnknown Status~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotUnknown Status~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2021 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Unknown Status → Completed

  5. Jan 2021 — Mar 2021 [monthly]

    Unknown Status PHASE3

▶ Show 3 earlier versions

  1. Mar 2020 — Jan 2021 [monthly]

    Unknown Status PHASE3

    Status: Active Not Recruiting → Unknown Status

  2. Jun 2018 — Mar 2020 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

    First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • European Organisation for Research and Treatment of Cancer - EORTC
  • Hoffmann-La Roche
Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations